CAR (Chimeric antigen receptor, CAR)-T is a technique for modifying immune cells called T cells in the lab such that they can detect and destroy cancer cells. CAR T-cell therapy is sometimes referred to as a sort of cell-based gene therapy as it includes changing the gene inside T cells that empowers them to attack cancer.
CAR-T cell therapy generally entails extracting T cells from the bloodstream and implanting a new gene into those cells that allows them to spot malignancy. T cells are injected back into the bloodstream of patients after the gene is introduced. After the injection they get multiple and then generate a different types of immune responses targeted at destroying cancer cells. There are different types of tumours that found in humans and all these tumours have distinct antigens. As per the antigen of a particular tumour each CAR is specifically tailored.
Report Key Takeaways
The healthcare bodies such as The US Food and Drug Administration (FDA) have approved CAR-T cell treatments to treat certain lymphomas and leukaemias, as well as multiple myeloma. CAR-T cell therapy is usually come into practice and implemented in case all other options have been exhausted.
Some of the approved CAR T-cell therapies include:
- Lisocabtagene maraleucel (liso-cel)
- Tisagenlecleucel (tisa-cel)
- Axicabtagene ciloleucel (axi-cel )
- Brexucabtagene autoleucel (brexu-cel)
- Idecabtagene vicleucel (ide-cel)
Although CAR-T cell therapy is still in its early stages, the recent studies conducted by various researchers certainly show promising results. For instance, a 2020 trial followed children with acute lymphoblastic leukaemia (ALL). Over 85% of children with ALL went into complete remission immediately after therapy, and among these children 60% remained completely cancer-free 12 months later.
Recent Developments Related to CAR-T
- The China National Medical Products Administration has formally given acceptance to the New Drug Application for Equecabtagene Autoleucel. This is developed jointly by the IASO Biotherapeutics and Innovent Biologics, Inc. This antigen CAR-T cell therapy is approved as a complete match for humans.
- Novartis announced that they have received the approval from the US (FDA) for the latest Kymriah®, CAR-T cell therapy. The approval is based on the results of the Phase II ELARA trial, a single-arm, open-label experiment in which 90 patients were evaluated for efficacy for a median of 17 months. This therapy is developed for the treatment of adult patients who are having refractory or relapsed follicular lymphoma (FL).
Major Players Working on CAR-T
Some of the leading companies that work closely and develop CAR-T cell therapies are Aurora Biopharma, Inc., BioAtla LLC., AbbVie Inc., CARTherics, Amgen, Inc., Carina Biotech, and Atara Biotherapeutics, Inc. A detailed overview of these companies, including their major achievements, product launches, recent studies, and pipeline projects, is thoroughly covered in this pipeline insight.
Key Reasons to Purchase This Report
- A complete outlook of the CAR-T cell Therapy pipeline arena is covered in this pipeline insight, which covers the details regarding the diseases and treatment guidelines.
- A detailed coverage of major acquisitions, product launches collaborations, expansion, and licensing that are taking place across the globe and that are related to the CAR-T with special emphasis on emerging trends.
- The pipeline insight covers the in-depth assessment of successfully developed drugs along with their mechanisms, recent clinical research studies, and ongoing product development, including major technologies.
- Players operating in this field will get the key insights about the major things happening in this whole industry, coupled with the strategic outlook of leading players operating in related fields to the CAR-T.